J Rheum Dis.  2012 Oct;19(5):262-269. 10.4078/jrd.2012.19.5.262.

Frequency of Metabolic Syndrome in Female Patients with Systemic Sclerosis: A Preliminary Report

• Lee SG
• Kim JM
• Lee SH
• Kim KH
• Choi SA
• Park EK
• Jung WJ
• Park YE
• Park SH
• Lee JW
• Baek SH
• Lee JH
• Kim GT

• KMID: 1438534
• DOI: http://doi.org/10.4078/jrd.2012.19.5.262

Abstract

OBJECTIVE
A higher prevalence of metabolic syndrome (MetS) has been described in various rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, but no direct studies have investigated the prevalence of MetS in systemic sclerosis (SSc) patients compared with the general population. We compared the frequency of MetS and insulin resistance, as measured by Homeostatic assessment model-insulin resistance (HOMA-IR) between female SSc patients and healthy subjects.
METHODS
In a cross-sectional setting, 35 female SSc patients and 84 age and sex-matched healthy subjects were consecutively recruited at a single center of a tertiary hospital between 2009 and 2010. MetS was defined according to the National Cholesterol Education Program's Adult Treatment Panel (NCEP-ATP III) 2004 criteria, using the Asian criteria for central obesity.
RESULTS
The frequency of MetS was not significantly higher in SSc patients (20.0%) than in healthy subjects (14.3%, p=0.425), but SSc patients had an increased insulin resistance measured by HOMA-IR (p=0.001). Significantly more patients with SSc had increased triglyceride concentrations (p=0.004) and fewer SSc patients tended to meet the waist circumference criterion (p=0.051) according to the individual MetS features. Additionally, there were no significant differences in age, high-sensitivity C-reactive protein, body mass index, HOMA-IR, disease duration, cumulative glucocorticoids dose, modified Rodnan skin score or the proportion of limited SSc cases according to the absence or presence of MetS in SSc patients.
CONCLUSION
Unlike other rheumatic diseases, our preliminary report did not show a significant difference in the prevalence of MetS between female SSc patients and healthy subjects.

Keyword

Systemic sclerosis; Metabolic syndrome; Insulin resistance

MeSH Terms

Adult
Arthritis, Rheumatoid
Asian Continental Ancestry Group
Body Mass Index
C-Reactive Protein
Cholesterol
Female
Glucocorticoids
Humans
Insulin Resistance
Lupus Erythematosus, Systemic
Prevalence
Rheumatic Diseases
Scleroderma, Systemic
Skin
Tertiary Care Centers
Waist Circumference
C-Reactive Protein
Cholesterol
Glucocorticoids

Reference

1. Guiducci S, Giacomelli R, Cerinic MM. Vascular complications of scleroderma. Autoimmun Rev. 2007. 6:520–523.

2. Borba EF, Borges CT, Bonfá E. Lipoprotein profile in limited systemic sclerosis. Rheumatol Int. 2005. 25:379–383.

3. Abraham DJ, Krieg T, Distler J, Distler O. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford). 2009. 48:Suppl 3. iii3–iii7.

4. Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford). 2008. 47:578–583.

5. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev. 2011. 10:259–266.

6. Au K, Singh MK, Bodukam V, Bae S, Maranian P, Ogawa R, et al. Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. Arthritis Rheum. 2011. 63:2078–2090.

7. Sidiropoulos PI, Karvounaris SA, Boumpas DT. Metabolic syndrome in rheumatic diseases: epidemiology, pathophysiology, and clinical implications. Arthritis Res Ther. 2008. 10:207.

8. Santos MJ, Fonseca JE. Metabolic syndrome, inflammation and atherosclerosis-the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port. 2009. 34:590–598.

9. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003. 108:1546–1551.

10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association. National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005. 112:2735–2752.

11. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006. 23:469–480.

12. Assmann G, Guerra R, Fox G, Cullen P, Schulte H, Willett D, et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol. 2007. 99:541–548.

13. Yiu KH, Tse HF, Mok MY, Lau CS. Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nat Rev Rheumatol. 2011. 7:609–618.

14. Singh B, Saxena A. Surrogate markers of insulin resistance: A review. World J Diabetes. 2010. 1:36–47.

15. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980. 23:581–590.

16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988. 15:202–205.

17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985. 28:412–419.

18. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis. 2006. 186:367–373.

19. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996. 49:1373–1379.

20. La Montagna G, Cacciapuoti F, Buono R, Manzella D, Mennillo GA, Arciello A, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res. 2007. 4:130–135.

21. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis. 2007. 66:28–33.

22. Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis. 2008. 196:756–763.

23. Dao HH, Do QT, Sakamoto J. Increased frequency of metabolic syndrome among Vietnamese women with early rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. 2010. 12:R218.

24. Crowson CS, Myasoedova E, Davis JM 3rd, Matteson EL, Roger VL, Therneau TM, et al. Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease. J Rheumatol. 2011. 38:29–35.

25. Karimi M, Mazloomzadeh S, Kafan S, Amirmoghadami H. The frequency of metabolic syndrome in women with rheumatoid arthritis and in controls. Int J Rheum Dis. 2011. 14:248–254.

26. Sahebari M, Goshayeshi L, Mirfeizi Z, Rezaieyazdi Z, Hatef MR, Ghayour-Mobarhan M, et al. Investigation of the association between metabolic syndrome and disease activity in rheumatoid arthritis. Scientific World Journal. 2011. 11:1195–1205.

27. Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007. 66:208–214.

28. Bultink IE, Turkstra F, Diamant M, Dijkmans BA, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. Clin Exp Rheumatol. 2008. 26:32–38.

29. Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J, Rodríguez del Aguila MD, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008. 17:849–859.

30. Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R, Berman H, et al. SLE Study Group of the Argentinean Society of Rheumatology. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009. 18:1019–1025.

31. Malesci D, Niglio A, Mennillo GA, Buono R, Valentini G, La Montagna G. High prevalence of metabolic syndrome in patients with ankylosing spondylitis. Clin Rheumatol. 2007. 26:710–714.

32. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010. 8:331–334.

33. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005. 111:1448–1454.

34. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999. 16:442–443.

35. Hanley AJ, Karter AJ, Festa A, D'Agostino R Jr, Wagenknecht LE, Savage P, et al. Insulin Resistance Atherosclerosis Study. Factor analysis of metabolic syndrome using directly measured insulin sensitivity: The Insulin Resistance Atherosclerosis Study. Diabetes. 2002. 51:2642–2647.

36. Romano M, Guagnano MT, Pacini G, Vigneri S, Falco A, Marinopiccoli M, et al. Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women. J Clin Endocrinol Metab. 2003. 88:5321–5326.

37. Mok MY, Lau CS, Chiu SS, Tso AW, Lo Y, Law LS, et al. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum. 2011. 63:1387–1395.

38. Hettema ME, Zhang D, de Leeuw K, Stienstra Y, Smit AJ, Kallenberg CG, et al. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther. 2008. 10:R49.

39. Choi SH, Ahn CW, Cha BS, Chung YS, Lee KW, Lee HC, et al. The prevalence of the metabolic syndrome in Korean adults: comparison of WHO and NCEP criteria. Yonsei Med J. 2005. 46:198–205.

40. Kang YH, Min HG, Kim IJ, Kim YK, Son SM. Comparison of alanine aminotransferase, white blood cell count, and uric acid in their association with metabolic syndrome: a study of Korean adults. Endocr J. 2008. 55:1093–1102.